Literature DB >> 16545009

Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.

F Van Leth1, B S Kappelhoff, D Johnson, M H Losso, A Boron-Kaczmarska, M S Saag, J-M Livrozet, D B Hall, J Leith, A D R Huitema, F W Wit, J H Beijnen, J M A Lange.   

Abstract

Optimal adherence is essential for successful antiretroviral therapy. We analyzed the relation between minimum plasma drug concentration (Cmin) and total drug exposure over 24 hr (AUC24) with virologic failure for therapy-adherent patients in the nevirapine (NVP) and efavirenz (EFV) groups of the double nonnucleoside study (2NN), which compared the efficacy of NVP and/or EFV together with stavudine and lamivudine. The objective was to find cutoff values of the Cmin and AUC24 below which the risk of virologic failure increased. The relation between Cmin and AUC24 with virologic failure (never a plasma viral load [pVL] < 50 copies/ml or a rebound to two consecutive pVL > 50 copies/ml) was analyzed with proportional hazard analyses. Data were censored at end of study or change of allocated treatment. The risk of virologic failure with NVP (n = 511) started to increase at a Cmin < 3.1 mg/L (hazard ratio [HR], 1.33; 95% confidence interval [CI], 0.89-1.97), but there was no cutoff value below which a statistically significant increased risk occurred. Neither was such a cutoff point identified for the AUC24. The risk of virologic failure with EFV (n = 312) was significantly increased at a Cmin < 1.1 mg/L (HR, 1.95; 95% CI, 1.08-3.54) and an AUC24 < 40 mg x hr x L1 (HR, 1.95; 95% CI, 1.07-3.54). Both cutoff values represent the median values for adherent patients. These associations were driven by patients from Thailand. Adjusting for geographical region made the association between Cmin and AUC24 with virologic failure statistically nonsignificant. The sensitivity of the Cmin values was too low (29% for NVP, 64% for EFV) to be an adequate predictor for virologic failure. We conclude that identifying the Cmin value for the sole purpose of predicting virologic failure in patients who report to be adherent to NVP or EFV is questionable because of the absence of a concentration-response relation (NVP) or the low sensitivity for such a cutoff value (NVP and EFV).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545009     DOI: 10.1089/aid.2006.22.232

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  27 in total

1.  AIDS diarrhea and antiretroviral drug concentrations: a matched-pair cohort study in Port au Prince, Haiti.

Authors:  Rebecca Dillingham; Paul Leger; Carole-Anne Beauharnais; Erica Miller; Angela Kashuba; Steven Jennings; Kathryn Dupnik; Amidou Samie; Etna Eyma; Richard Guerrant; Jean Pape; Daniel Fitzgerald
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

3.  Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.

Authors:  Andrzej Bienczak; Paolo Denti; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Diana M Gibb; David Burger; Ann S Walker; Helen McIlleron
Journal:  AIDS       Date:  2017-04-24       Impact factor: 4.177

4.  Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.

Authors:  John M Cortez; Rafaela Quintero; John A Moss; Martin Beliveau; Thomas J Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

5.  Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.

Authors:  Retsilisitsoe R Moholisa; Michael Schomaker; Louise Kuhn; Sandra Castel; Lubbe Wiesner; Ashraf Coovadia; Renate Strehlau; Faeezah Patel; Francoise Pinillos; Elaine J Abrams; Gary Maartens; Helen McIlleron
Journal:  Pediatr Infect Dis J       Date:  2016-12       Impact factor: 2.129

6.  The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Authors:  Imke H Bartelink; Rada M Savic; Grant Dorsey; Theodore Ruel; David Gingrich; Henriette J Scherpbier; Edmund Capparelli; Vincent Jullien; Sera L Young; Jane Achan; Albert Plenty; Edwin Charlebois; Moses Kamya; Diane Havlir; Francesca Aweeka
Journal:  Pediatr Infect Dis J       Date:  2015-03       Impact factor: 2.129

7.  CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W C Sagoe; Ernest Kenu; Michael H Court
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

8.  The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

Authors:  Filip Josephson; Maria C H Andersson; Leo Flamholc; Magnus Gisslén; Lars Hagberg; Vidar Ormaasen; Anders Sönnerborg; Jan Vesterbacka; Ylva Böttiger
Journal:  Eur J Clin Pharmacol       Date:  2009-12-05       Impact factor: 2.953

9.  Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.

Authors:  Karen Cohen; Alison Grant; Collet Dandara; Helen McIlleron; Lindiwe Pemba; Katherine Fielding; Salome Charalombous; Gavin Churchyard; Peter Smith; Gary Maartens
Journal:  Antivir Ther       Date:  2009

Review 10.  Efavirenz--still first-line king?

Authors:  Brookie M Best; Miguel Goicoechea
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.